0 CHECKOUT

Acinetobacter Infections - Pipeline Review, H1 2015

  • ID: 3293065
  • May 2015
  • 114 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Achaogen Inc.
  • AvidBiotics Corp.
  • LegoChem Biosciences, Inc
  • Northern Antibiotics Oy
  • Omnia Molecular Ltd.
  • Sealife PHARMA GMBH
  • MORE

Acinetobacter Infections - Pipeline Review, H1 2015

Summary

This, ‘Acinetobacter Infections - Pipeline Review, H1 2015’, provides an overview of the Acinetobacter Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Achaogen Inc.
  • AvidBiotics Corp.
  • LegoChem Biosciences, Inc
  • Northern Antibiotics Oy
  • Omnia Molecular Ltd.
  • Sealife PHARMA GMBH
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Acinetobacter Infections Overview
Therapeutics Development
Pipeline Products for Acinetobacter Infections - Overview
Pipeline Products for Acinetobacter Infections - Comparative Analysis
Acinetobacter Infections - Therapeutics under Development by Companies
Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes
Acinetobacter Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Acinetobacter Infections - Products under Development by Companies
Acinetobacter Infections - Products under Investigation by Universities/Institutes
Acinetobacter Infections - Companies Involved in Therapeutics Development
Achaogen Inc.
Adenium Biotech ApS
AmpliPhi Biosciences Corporation
Aridis Pharmaceuticals LLC
AstraZeneca PLC
AvidBiotics Corp.
ConjuGon, Inc.
Emergent BioSolutions Inc.
FAB Pharma
LegoChem Biosciences, Inc
Melinta Therapeutics, Inc
Microbiotix, Inc.
Northern Antibiotics Oy
Nosopharm SAS
Novan, Inc.
Omnia Molecular Ltd.
Pfizer Inc.
Phylogica Limited
Sarepta Therapeutics, Inc.
Sealife PHARMA GMBH
Shionogi & Co., Ltd.
Synthetic Biologics, Inc.
Techulon, Inc.
Trana Discovery, Inc.
Vaxdyn, S.L.
Acinetobacter Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-3APO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AA-139 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACHN-975 Prodrug - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide for Acinetobacter Baumannii Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologics for Acinetobacter Baumanii - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BXN-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EV-035 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fab-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GN-4474 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCB-100200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBX-1162 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDN-0057 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDN-0058 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDN-0059 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDN-0060 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-7061 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-739 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-741 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOSO-95300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-4428 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RXP-873 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-649266 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Acinetobacter baumannii Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYN-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VXD-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VXD-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acinetobacter Infections - Recent Pipeline Updates
Acinetobacter Infections - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Acinetobacter Infections, H1 2015
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Acinetobacter Infections - Pipeline by Achaogen Inc., H1 2015
Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H1 2015
Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corporation, H1 2015
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2015
Acinetobacter Infections - Pipeline by AstraZeneca PLC, H1 2015
Acinetobacter Infections - Pipeline by AvidBiotics Corp., H1 2015
Acinetobacter Infections - Pipeline by ConjuGon, Inc., H1 2015
Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc., H1 2015
Acinetobacter Infections - Pipeline by FAB Pharma, H1 2015
Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H1 2015
Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015
Acinetobacter Infections - Pipeline by Microbiotix, Inc., H1 2015
Acinetobacter Infections - Pipeline by Northern Antibiotics Oy, H1 2015
Acinetobacter Infections - Pipeline by Nosopharm SAS, H1 2015
Acinetobacter Infections - Pipeline by Novan, Inc., H1 2015
Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H1 2015
Acinetobacter Infections - Pipeline by Pfizer Inc., H1 2015
Acinetobacter Infections - Pipeline by Phylogica Limited, H1 2015
Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2015
Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H1 2015
Acinetobacter Infections - Pipeline by Synthetic Biologics, Inc., H1 2015
Acinetobacter Infections - Pipeline by Techulon, Inc., H1 2015
Acinetobacter Infections - Pipeline by Trana Discovery, Inc., H1 2015
Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Acinetobacter Infections Therapeutics - Recent Pipeline Updates, H1 2015
Acinetobacter Infections - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Acinetobacter Infections, H1 2015
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Achaogen Inc.
Adenium Biotech ApS
AmpliPhi Biosciences Corporation
Aridis Pharmaceuticals LLC
AstraZeneca PLC
AvidBiotics Corp.
ConjuGon, Inc.
Emergent BioSolutions Inc.
FAB Pharma
LegoChem Biosciences, Inc
Melinta Therapeutics, Inc
Microbiotix, Inc.
Northern Antibiotics Oy
Nosopharm SAS
Novan, Inc.
Omnia Molecular Ltd.
Pfizer Inc.
Phylogica Limited
Sarepta Therapeutics, Inc.
Sealife PHARMA GMBH
Shionogi & Co., Ltd.
Synthetic Biologics, Inc.
Techulon, Inc.
Trana Discovery, Inc.
Vaxdyn, S.L.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.